Tiziana Life Sciences Ltd./$TLSA
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Tiziana Life Sciences Ltd.
Tiziana Life Sciences Ltd is a clinical-stage biotechnology company that specializes in developing transformative therapies for neurodegenerative and neuroinflammatory diseases. The company's clinical pipeline includes drug assets for Non-Active Secondary Progressive Multiple Sclerosis, Multiple System Atrophy, Alzheimer's, and Amyotrophic Lateral Sclerosis. The company's mission is to design and deliver next-generation immunotherapies for neurodegenerative and neuroinflammatory diseases. The company's main immunotherapeutic candidate, Foralumab (TZLS-401), is being developed for Non-Active Secondary Progressive Multiple Sclerosis, Alzheimer's, and other CNS indications.
- Ticker
- $TLSA
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 10
- Headquarters
- London, United Kingdom
- Website
- www.tizianalifesciences.com
TLSA Metrics
BasicAdvanced
$136M
-
-$0.16
0.44
-
Price and volume
Market cap
$136M
Beta
0.44
52-week high
$2.10
52-week low
$0.76
Average daily volume
681K
Financial strength
Current ratio
0.763
Quick ratio
0.722
Long term debt to equity
4.5
Total debt to equity
8.769
Interest coverage (TTM)
-1,174.00%
Profitability
EBITDA (TTM)
-21.12
Management effectiveness
Return on assets (TTM)
-115.96%
Return on equity (TTM)
-924.32%
Valuation
Price to book
2,436.19
Price to tangible book (TTM)
2,436.19
Price to free cash flow (TTM)
-9.652
Free cash flow yield (TTM)
-10.36%
Free cash flow per share (TTM)
-0.109
Growth
Earnings per share change (TTM)
40.12%
3-year earnings per share growth (CAGR)
0.91%
10-year earnings per share growth (CAGR)
2.04%
What the Analysts think about TLSA
Analyst ratings (Buy, Hold, Sell) for Tiziana Life Sciences Ltd. stock.
Analyst projections of the future price of Tiziana Life Sciences Ltd. stock.
TLSA Financial Performance
Revenues and expenses
TLSA Earnings Performance
Company profitability
Upcoming events
No upcoming events
TLSA News
AllArticlesVideos
Tiziana completes dosing in Phase 2 Alzheimer's trial of intranasal foralumab
Proactive Investors2 days ago
Tiziana Life Sciences seeks FDA orphan drug status for nasal MSA therapy
Proactive Investors3 weeks ago
Tiziana doses first three patients in ALS trial of nasal antibody foralumab
Proactive Investors3 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.